93 results
POS AM
QNRX
Quoin Pharmaceuticals Ltd
29 Mar 24
Prospectus update (post-effective amendment)
4:11pm
with regulatory standards and requirements and insider trading.
We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees … to the FDA and non-U.S. regulators, to comply with healthcare fraud and abuse laws and regulations in the United States and abroad, to report financial
424B3
QNRX
Quoin Pharmaceuticals Ltd
8 Mar 24
Prospectus supplement
4:06pm
, inquiry, or trading suspension by the SEC alleging: (i) a violation of the anti-fraud provisions of the federal securities laws; (ii) violations of the anti … of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence
424B3
wwi1o rjxcwvpuxk4y
8 Mar 24
Prospectus supplement
4:04pm
8-K
EX-10.1
4a6mxj4jg 4vj7cq
8 Mar 24
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
4:01pm
424B4
6fv7hm8h1z7phxn3
6 Mar 24
Prospectus supplement with pricing info
5:07pm
424B3
n9zdc70i9mv3as1qfax
4 Mar 24
Prospectus supplement
5:27pm
424B3
n2htzuhsemdj618
31 Jan 24
Prospectus supplement
12:00am
8-K
EX-10.1
jwguej2z4vszelb5z
30 Jan 24
Entry into a Material Definitive Agreement
4:05pm
424B3
rak6f
9 Nov 23
Prospectus supplement
5:15pm
424B3
gwgcqtit5r8c qw6
14 Sep 23
Prospectus supplement
4:38pm
8-K
EX-10.1
sn774gq
12 Sep 23
Entry into a Material Definitive Agreement
6:01pm
424B3
hn47hmfciy l1krreug
3 Aug 23
Prospectus supplement
4:51pm